Sarcosine — Safety, Research, Risks & Legal Status

Not medical advice. Sarcosine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	N-methylglycine, N-methylaminoacetic acid, sarcosinic acid, monomethylglycine
Category	Nootropic
Drug class	GlyT1 (type-1 glycine transporter) inhibitor / NMDA-receptor glycine-site co-agonist facilitator
Chemical identity	N-methylglycine, an endogenous amino-acid derivative and one-carbon metabolism intermediate
Route	Oral
Primary research indication	Adjunctive treatment of schizophrenia (also studied in depression and OCD)
Regulatory status	Sold OTC as a dietary supplement in the US; not an FDA-approved drug
Evidence level	Small double-blind RCTs and one meta-analysis; results mixed, no large confirmatory trial
US legal status	In the United States, sarcosine is sold and marketed as a dietary supplement (an amino-acid derivative under the DSHEA framework) and is available over the counter from nootropic vendors. It is not an FDA-approved drug for any indication, and no supplement may lawfully claim to diagnose, treat, cure, or prevent schizophrenia, depression, OCD, or any other disease; such claims are not evaluated by the FDA. Its use in psychiatry to date has been off-label and investigational, as an academic-trial adjunct, not as an approved medication. Note that purpose-built sarcosine-based glycine-transporter drugs (for example Org 25935 and AMG 747) are separate investigational compounds, distinct from the OTC supplement.

What is Sarcosine?

Sarcosine (N-methylglycine) is a naturally occurring amino-acid derivative and a type-1 glycine transporter (GlyT1) inhibitor. By slowing glycine reuptake at the synapse, it is proposed to raise glycine availability at the glycine co-agonist ("modulatory") site of the NMDA glutamate receptor, thereby enhancing NMDA-receptor function. It is an endogenous human metabolite, an intermediate in the interconversion of glycine and the choline/methionine one-carbon pathway, and it occurs in the normal diet, so it is not a foreign xenobiotic. It has been studied mainly as an add-on to antipsychotics in schizophrenia, and in smaller trials for major depression and OCD. Separately, and in an unrelated context, sarcosine is known in oncology as a candidate metabolite biomarker in prostate cancer.

How it works

Sarcosine's proposed primary mechanism is inhibition of the type-1 glycine transporter (GlyT1), which normally clears glycine from the synaptic cleft near excitatory synapses. By slowing glycine reuptake, sarcosine is thought to increase local glycine concentrations at the strychnine-insensitive glycine co-agonist site of the NMDA receptor, where glycine (or D-serine) must bind alongside glutamate for the channel to open. Enhancing occupancy of this site is proposed to potentiate NMDA-receptor-mediated glutamatergic neurotransmission. This is relevant to the "NMDA-hypofunction" hypothesis of schizophrenia, in which reduced NMDA signaling is thought to contribute to negative and cognitive symptoms; sarcosine may also act as a weak direct agonist at the glycine site. Sarcosine is additionally an endogenous intermediate in one-carbon (glycine/choline/methionine) metabolism, interconverted with glycine by the enzymes glycine N-methyltransferase and sarcosine dehydrogenase. The mechanism is well-reasoned and supported by animal models, but the degree to which oral supplement doses meaningfully raise central glycine site occupancy in humans is not firmly established.

Background & history

Sarcosine was first identified in the 19th century as a product of creatine and glycine chemistry and is a long-known natural metabolite; the name derives from the Greek for "flesh," reflecting its early isolation from muscle-related material. Modern research interest emerged in the 2000s from the NMDA-hypofunction hypothesis of schizophrenia, when Taiwanese investigators (notably groups associated with Hsien-Yuan Lane and colleagues) ran a series of adjunctive-treatment trials in schizophrenia, depression, and OCD across the 2000s and 2010s. In parallel, a widely publicized 2009 metabolomics study proposed sarcosine as an oncometabolite and potential biomarker of prostate cancer progression, opening a separate and still-unresolved oncology research line. The compound was never developed into an approved psychiatric drug; it instead became available as an over-the-counter nootropic supplement, while pharmaceutical GlyT1 programs pursued more potent purpose-built inhibitors.

What the research says

Human data are modest and mixed rather than definitive. In schizophrenia, several small double-blind randomized controlled trials tested sarcosine (commonly 2 g/day) added to antipsychotics; some reported improvement in positive, negative, and general symptoms with good tolerability, particularly in non-refractory patients and those not on clozapine, while other studies (including in drug-free patients and in clozapine-treated patients) found no benefit. A 2020 systematic review and meta-analysis of double-blind RCTs (roughly six trials, a few hundred participants total) found no statistically significant pooled effect at pre-set timepoints, driven by marked heterogeneity between trials, though a subset of chronic non-refractory patients appeared to respond. For major depression, a single small (about 40-patient) 6-week randomized, citalopram-controlled trial reported that sarcosine outperformed citalopram on depression rating scales with good tolerability, an encouraging but unreplicated signal. For OCD, only a 10-week open-label study (no placebo control) exists, with a partial response in roughly a third of patients. Overall: promising, mechanistically coherent, but based on small, mostly single-site trials with inconsistent results and no large confirmatory trials.

Reported effects

Investigated as an adjunct to antipsychotics for positive, negative, and general symptoms of schizophrenia (results inconsistent across trials)
Preliminary single-trial signal for improving depressive symptoms in major depressive disorder
Open-label-only signal for reducing obsessive-compulsive symptom severity
Proposed pro-cognitive effect via enhanced NMDA-receptor signaling (weak, inconsistent human evidence)
Reported by users and small studies as generally well tolerated with mild or no side effects at studied doses
Marketed by supplement vendors for mood and emotional well-being (claims not FDA-evaluated)

Dosing & administration (informational)

Informational only, not a protocol or recommendation. In the published psychiatric literature, sarcosine was most often given orally at about 2 g/day (with some studies exploring a 500-2000 mg/day range), typically as an add-on to existing antipsychotic or antidepressant treatment over 6-week or longer study periods, sometimes titrated up gradually. An upper safe limit has not been formally established. These figures describe what appeared in small research studies and do not constitute dosing guidance; anyone considering sarcosine should consult a qualified clinician, especially given its interaction with the same neurotransmitter systems targeted by prescription psychiatric medications.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Human safety data come almost entirely from small, short (6-10 week) trials; long-term safety is not established
As an NMDA-facilitating agent, theoretical concern exists about excitotoxicity or seizure threshold with excessive dosing, though this has not been demonstrated at studied doses
Mild gastrointestinal upset is the most commonly reported adverse effect; some users report irritability, insomnia, or overstimulation
Elevated sarcosine has been studied as a candidate biomarker associated with prostate cancer; a causal or supplement-driven risk is not established, but this is an open question and a reason for caution in older men and those with prostate concerns
It modulates the same glutamatergic/NMDA system targeted by psychiatric medications, so it should not be combined with prescribed psychiatric drugs without clinician oversight
Not studied in pregnancy, lactation, children, or renal/hepatic impairment; avoid in these populations
Supplement products are not premarket-tested by the FDA, so purity and dose accuracy depend entirely on the manufacturer

Drug & supplement interactions

T
h
e
m
o
s
t
i
m
p
o
r
t
a
n
t
i
n
t
e
r
a
c
t
i
o
n
c
o
n
c
e
r
n
i
s
w
i
t
h
p
r
e
s
c
r
i
p
t
i
o
n
p
s
y
c
h
i
a
t
r
i
c
m
e
d
i
c
a
t
i
o
n
s
.
S
a
r
c
o
s
i
n
e
w
a
s
s
t
u
d
i
e
d
s
p
e
c
i
f
i
c
a
l
l
y
a
s
a
n
a
d
d
-
o
n
t
o
a
n
t
i
p
s
y
c
h
o
t
i
c
s
,
s
o
i
t
a
c
t
s
o
n
t
h
e
s
a
m
e
g
l
u
t
a
m
a
t
e
r
g
i
c
/
N
M
D
A
a
x
i
s
t
h
o
s
e
d
r
u
g
s
a
n
d
t
h
e
i
r
t
a
r
g
e
t
s
t
o
u
c
h
;
c
o
m
b
i
n
i
n
g
i
t
w
i
t
h
a
n
t
i
p
s
y
c
h
o
t
i
c
s
,
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
,
o
r
o
t
h
e
r
C
N
S
-
a
c
t
i
v
e
a
g
e
n
t
s
s
h
o
u
l
d
o
n
l
y
b
e
d
o
n
e
u
n
d
e
r
c
l
i
n
i
c
i
a
n
s
u
p
e
r
v
i
s
i
o
n
.
N
o
t
a
b
l
y
,
i
n
t
r
i
a
l
s
s
a
r
c
o
s
i
n
e
d
i
d
n
o
t
a
d
d
b
e
n
e
f
i
t
(
a
n
d
m
a
y
n
o
t
c
o
m
b
i
n
e
f
a
v
o
r
a
b
l
y
)
i
n
p
a
t
i
e
n
t
s
t
r
e
a
t
e
d
w
i
t
h
c
l
o
z
a
p
i
n
e
,
s
u
g
g
e
s
t
i
n
g
m
e
c
h
a
n
i
s
m
-
d
e
p
e
n
d
e
n
t
i
n
t
e
r
a
c
t
i
o
n
s
.
B
e
c
a
u
s
e
s
a
r
c
o
s
i
n
e
f
a
c
i
l
i
t
a
t
e
s
N
M
D
A
t
r
a
n
s
m
i
s
s
i
o
n
,
t
h
e
o
r
e
t
i
c
a
l
c
a
u
t
i
o
n
a
p
p
l
i
e
s
w
i
t
h
o
t
h
e
r
N
M
D
A
-
a
c
t
i
v
e
a
g
e
n
t
s
(
f
o
r
e
x
a
m
p
l
e
D
-
s
e
r
i
n
e
,
g
l
y
c
i
n
e
,
D
-
c
y
c
l
o
s
e
r
i
n
e
,
o
r
N
M
D
A
a
n
t
a
g
o
n
i
s
t
s
l
i
k
e
m
e
m
a
n
t
i
n
e
o
r
k
e
t
a
m
i
n
e
)
,
w
h
e
r
e
c
o
m
b
i
n
e
d
e
f
f
e
c
t
s
a
r
e
n
o
t
w
e
l
l
c
h
a
r
a
c
t
e
r
i
z
e
d
.
I
t
i
n
t
e
r
s
e
c
t
s
o
n
e
-
c
a
r
b
o
n
/
m
e
t
h
y
l
a
t
i
o
n
m
e
t
a
b
o
l
i
s
m
(
g
l
y
c
i
n
e
,
c
h
o
l
i
n
e
,
m
e
t
h
i
o
n
i
n
e
,
S
A
M
e
)
,
t
h
o
u
g
h
t
h
e
c
l
i
n
i
c
a
l
s
i
g
n
i
f
i
c
a
n
c
e
o
f
d
i
e
t
a
r
y
o
r
s
u
p
p
l
e
m
e
n
t
a
l
o
v
e
r
l
a
p
i
s
u
n
c
l
e
a
r
.

Who should avoid it

Do not use as a substitute for prescribed antipsychotic or antidepressant treatment
Avoid combining with prescription psychiatric medications without a clinician's oversight
Avoid in pregnancy, breastfeeding, and in children, where it is unstudied
Caution or avoidance is prudent in men with prostate cancer or elevated prostate-cancer risk, given sarcosine's biomarker association
Do not assume the mixed and small trial evidence establishes efficacy for any condition
Avoid high or escalating doses beyond studied ranges, since an upper safe limit is not established

How it is commonly combined

Sarcosine is sometimes combined by users with other glycine-site or NMDA-modulating agents (such as glycine, D-serine, or D-cycloserine) on the theory of additive NMDA facilitation, but there is little controlled human data on these combinations and the safety of stacking NMDA-active compounds is not established. It is not the same as, and should not be conflated with, prescription adjuncts. There is no rigorous evidence that any "stack" improves outcomes over sarcosine alone, and combining CNS-active supplements increases the difficulty of attributing effects or adverse events. Any combination with prescribed medication should be cleared with a clinician first.

Legal & regulatory. In the United States, sarcosine is sold and marketed as a dietary supplement (an amino-acid derivative under the DSHEA framework) and is available over the counter from nootropic vendors. It is not an FDA-approved drug for any indication, and no supplement may lawfully claim to diagnose, treat, cure, or prevent schizophrenia, depression, OCD, or any other disease; such claims are not evaluated by the FDA. Its use in psychiatry to date has been off-label and investigational, as an academic-trial adjunct, not as an approved medication. Note that purpose-built sarcosine-based glycine-transporter drugs (for example Org 25935 and AMG 747) are separate investigational compounds, distinct from the OTC supplement.

Quality & harm reduction

B
e
c
a
u
s
e
s
a
r
c
o
s
i
n
e
i
s
s
o
l
d
a
s
a
n
u
n
r
e
g
u
l
a
t
e
d
d
i
e
t
a
r
y
s
u
p
p
l
e
m
e
n
t
,
p
r
o
d
u
c
t
q
u
a
l
i
t
y
v
a
r
i
e
s
b
y
v
e
n
d
o
r
a
n
d
i
s
n
o
t
v
e
r
i
f
i
e
d
b
y
t
h
e
F
D
A
b
e
f
o
r
e
s
a
l
e
.
P
r
e
f
e
r
p
r
o
d
u
c
t
s
w
i
t
h
t
h
i
r
d
-
p
a
r
t
y
(
i
n
d
e
p
e
n
d
e
n
t
l
a
b
)
t
e
s
t
i
n
g
a
n
d
a
p
u
b
l
i
s
h
e
d
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
c
o
n
f
i
r
m
i
n
g
i
d
e
n
t
i
t
y
,
p
o
t
e
n
c
y
,
a
n
d
a
b
s
e
n
c
e
o
f
h
e
a
v
y
m
e
t
a
l
s
a
n
d
m
i
c
r
o
b
i
a
l
c
o
n
t
a
m
i
n
a
t
i
o
n
;
s
o
m
e
e
s
t
a
b
l
i
s
h
e
d
n
o
o
t
r
o
p
i
c
v
e
n
d
o
r
s
p
r
o
v
i
d
e
t
h
i
s
.
S
a
r
c
o
s
i
n
e
i
s
a
s
i
m
p
l
e
,
w
e
l
l
-
c
h
a
r
a
c
t
e
r
i
z
e
d
s
m
a
l
l
m
o
l
e
c
u
l
e
,
s
o
i
d
e
n
t
i
t
y
c
o
n
f
i
r
m
a
t
i
o
n
(
f
o
r
e
x
a
m
p
l
e
b
y
N
M
R
o
r
c
h
r
o
m
a
t
o
g
r
a
p
h
y
o
n
t
h
e
C
O
A
)
i
s
m
e
a
n
i
n
g
f
u
l
.
C
h
e
w
a
b
l
e
o
r
p
o
w
d
e
r
f
o
r
m
s
a
l
l
o
w
d
o
s
e
v
e
r
i
f
i
c
a
t
i
o
n
b
y
w
e
i
g
h
t
.
A
s
w
i
t
h
a
n
y
s
u
p
p
l
e
m
e
n
t
,
t
h
e
a
b
s
e
n
c
e
o
f
p
r
e
m
a
r
k
e
t
r
e
v
i
e
w
m
e
a
n
s
t
h
e
l
a
b
e
l
c
l
a
i
m
i
s
o
n
l
y
a
s
r
e
l
i
a
b
l
e
a
s
t
h
e
s
e
l
l
e
r
'
s
o
w
n
t
e
s
t
i
n
g
.

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Does sarcosine actually work for schizophrenia?

The evidence is genuinely mixed. Several small double-blind trials of about 2 g/day added to antipsychotics reported symptom improvement, especially in non-refractory patients not on clozapine, but other trials found no benefit, and a 2020 meta-analysis found no significant pooled effect because the trials were so heterogeneous. It is best described as a plausible, generally well-tolerated adjunct with inconsistent results, not an established treatment.

How is sarcosine thought to work?

It inhibits the GlyT1 glycine transporter, which is proposed to raise glycine levels at the NMDA receptor's glycine co-agonist site and thereby enhance NMDA-mediated glutamate signaling. This connects to the NMDA-hypofunction hypothesis of schizophrenia. The mechanism is well-reasoned and supported in animal models, but how strongly oral supplement doses affect the human brain is not firmly established.

Is sarcosine legal, and is it FDA-approved?

It is legal to sell in the US as a dietary supplement and is available over the counter. It is not an FDA-approved drug, and no product may lawfully claim to treat any disease. Any psychiatric use has been off-label and investigational.

What dose is used in studies?

This is informational only and not advice. Trials most often used about 2 g/day orally (with a broader 500-2000 mg/day range in some studies), usually as an add-on over several weeks. An upper safe limit has not been established. Anyone considering it should speak with a clinician, particularly because it interacts with the same systems as prescription psychiatric drugs.

Isn't sarcosine linked to prostate cancer?

Sarcosine was proposed in a 2009 metabolomics study as a candidate biomarker associated with prostate cancer progression, and it can be measured in urine and serum. Whether it plays a causal role, or whether supplementing raises risk, is unresolved and controversial, with some studies not confirming the association. It is a reasonable point of caution for men with prostate cancer or elevated risk, but not proof of harm.

Is sarcosine safe?

In short trials it was generally well tolerated, with mild GI upset the most common complaint and occasional reports of irritability or insomnia. However, safety data come from small, short studies; long-term safety, and use in pregnancy, children, or medical conditions, are not established. It should not replace prescribed treatment or be combined with psychiatric medication without clinician oversight.

References & further reading

PubMed: sarcosine N-methylglycine schizophrenia randomized double-blind add-on antipsychotic
PubMed: sarcosine efficacy cognitive schizophrenia systematic review meta-analysis double-blind
PubMed: glycine transporter-1 inhibition sarcosine major depressive disorder randomized citalopram controlled
PubMed: sarcosine obsessive compulsive disorder open-label GlyT1
PubMed: sarcosine oncometabolite prostate cancer biomarker metabolomics serum